Oncotarget

Reviews:

Pooling-analysis for diagnostic and prognostic value of MiRNA-100 in various cancers

Zhe Dou, Shuai Lin, Cong Dai, Ye Lu, Tian Tian, Meng Wang, Xinghan Liu, Yi Zheng, Peng Xu, Shanli Li, Qianwen Sheng and Zhijun Dai _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:62703-62715. https://doi.org/10.18632/oncotarget.18697

Metrics: PDF 508 views  |   HTML 1233 views  |   ?  


Abstract

Zhe Dou1,*, Shuai Lin1,*, Cong Dai1,*, Ye Lu2, Tian Tian1, Meng Wang1, Xinghan Liu1, Yi Zheng1, Peng Xu1, Shanli Li1, Qianwen Sheng1, Yujiao Deng1 and Zhijun Dai1

1Department of Oncology, Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710004, China

2Department of Student Affairs, Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710004, China

*ZD, SL and CD have contributed equally to this work

Correspondence to:

Zhijun Dai, email: dzj0911@126.com, dzj0911@ xjtu.edu.cn

Keywords: miRNA-100, diagnosis, prognosis, meta-analysis

Received: December 14, 2016    Accepted: May 15, 2017    Published: June 27, 2017

ABSTRACT

Many studies manifested miRNA-100 was deregulated in various cancers, which indicated that miRNA-100 might be a potential biomarker of cancer diagnosis and prognosis. However, the role of miRNA-100 was still uncertain. We searched for qualified studies using PubMed, EMBASE, Web of Science, Cochrane library and CNKI databases. The diagnostic effect was evaluated by the pooled sensitivity, specificity, and other indexes. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) for overall survival (OS) were calculated to assess the prognostic value. This meta-analysis included 7 and 19 studies about diagnosis and prognosis, respectively. The results of pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR) and diagnostic odds ratio (DOR) were 0.75 (95%CI: 0.71-0.78), 0.74 (95%CI: 0.69-0.78), 2.61 (95%CI: 1.81-3.76), 0.33 (95%CI: 0.24-0.45), 8.46 (95%CI: 4.85-14.77), respectively. And, the area under SROC curve (AUC) was 0.8141. We also found that lower expression of miRNA-100 in cancer tissues could significantly predict poorer prognosis in overall cancer (HR = 0.59, 95%CI: 0.39-0.90), especially in genital system tumors (HR = 0.42, 95%CI: 0.27-0.66, P = 0.431), bladder cancer (HR = 0.21, 95%CI: 0.06-0.73, P = 0.143) and esophageal squamous cell carcinoma (HR = 0.26, 95%CI: 0.13-0.52, P = 0.164). Our studies concluded that miRNA-100 has a certain value in diagnosis and it may indicate a poor prognosis of cancers.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 18697